EPHX2 and fatty liver disease: Follow-up studies evaluating the effects of Ephx2 disruption and pharmacologic strategies that promote the effects of EETs, including sEH inhibitors and stable EET analogs, in additional models of NAFLD/NASH remain necessary to elucidate the functional contribution of CYP-derived EETs to fatty liver disease.